Coronary artery diameter increase induced by a phosphodiesterase 5 inhibitor, E4021, in conscious pigs

Japanese Journal of Pharmacology

Volumn 77, Issue 1, 1998, Pages 99-102

  Adachi, Hideyuki ^a   Nishino, Mayu ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Conscious pig; Coronary diameter; Phosphodiesterase 5 inhibitor

Indexed keywords

1 [6 CHLORO 4 (3,4 METHYLENEDIOXYBENZYLAMINO) 2 QUINAZOLINYL] 4 PIPERIDINECARBOXYLIC ACID; GLYCERYL TRINITRATE; PHOSPHODIESTERASE INHIBITOR;

ANIMAL EXPERIMENT; AORTA PRESSURE; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; DRUG INFUSION; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; MALE; NONHUMAN; SWINE;

EID: 0031800581     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.77.99     Document Type: Article

References (15)

1. Beavo JA, Conti M and Heaslip RJ: Multiple cyclic nucleotide phosphodiesterase. Mol Pharmacol 46, 399-405 (1994)
2. Saeki T, Adachi H, Takase Y, Yoshitake S, Souda S and Saito I: A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J Pharmacol Exp Ther 272, 825-831 (1995)
3. Kodama K, Adachi H, Mori N and Saito I: Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs. Eur J Pharmacol 263, 93-99 (1994)
4. Adachi H: Effects of E4080, a novel bradycardic agent with a coronary vasodilating property, on coronary and systemic hemodynamics in conscious dogs. J Pharmacol Exp Ther 268, 133-138 (1994)
5. Adachi H, Tomoike H, Nishijima H, Hayashi Y, Yamada A and Nakamura M: Effects of verapamil and nitroglycerin on coronary and systemic hemodynamics in conscious dogs. J Pharmacol Exp Ther 241, 1072-1078 (1987)
6. Adachi H, Tomoike H, Nishijima H, Egashira S and Nakamura M: Sustained dilatation of large coronary artery by alpha-human atrial natriuretic peptide in conscious dogs: a comparison with nitroglycerin. Eur J Pharmacol 161, 189-196 (1989)
7. Lincoln TM: Cyclic GMP and mechanisms of vasodilation. Pharmao Ther 41, 479-502 (1989)
8. Silver PJ, Dundore RL, Bode DC, de Garavilla L, Buchholz RA, van Aller G, Hamel LT, Bacon E, Singh B, Lesher GY, Hlasta D and Pagani ED: Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor. J Pharmacol Exp Ther 271, 1143-1149 (1994)
9. Coste H and Grondin P: Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem Pharmacol 50, 1577-1585 (1995)
10. Delpy E and de Gouville ACM: Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization. Br J Pharmacol 118, 1377-1384 (1996)
11. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH and Gingell C: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impotence Res 8, 47-52 (1996)
12. Terrett NK, Bell AS, Brown D and Ellis P: Sildenafil (VIAGRA™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett 6, 1819-1824 (1996)
13. Hintze TH and Vatner SF: Reactive dilation of large coronary arteries in conscious dogs. Circ Res 54, 50-57 (1984)
14. Cigarini I, Adnot S, Chabrier PE, Viossat I, Braquet P and Gaujour B: Pulmonary vasodilator responses to atrial natriuretic factor and sodium nitroprusside. J Appl Physiol 67, 2269-2275 (1989)
15. Dinh-Xuan AT: Disorders of endothelium-dependent relaxation in pulmonary disease. Circulation 87, V-81-V-87 (1993)